Opus Genetics | Ocuphire Pharma

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on the development of gene therapies and ophthalmic treatments to address rare and debilitating inherited retinal diseases (IRDs) and other vision disorders. Formed through the all-stock acquisition of Opus Genetics by Ocuphire Pharma in October 2024, the combined entity adopted the Opus Genetics name and Nasdaq ticker symbol “IRD” to reflect its strategic focus on transformative genetic medicines for vision loss.

The company’s core mission is to restore and preserve vision by addressing the underlying genetic causes of severe retinal disorders that currently lack effective therapies. Its pipeline centers on multiple adeno-associated virus (AAV)-based gene therapy candidates, including programs targeting Leber congenital amaurosis (LCA5), BEST1-related diseases, and other mutations associated with retinitis pigmentosa and related conditions. These one-time, potentially durable treatments aim to deliver healthy copies of defective genes directly to retinal cells, offering hope for patients with historically untreatable forms of blindness.

In addition to its gene therapy portfolio, Opus Genetics continues to develop phentolamine ophthalmic solution 0.75%, an approved small-molecule therapy originally advanced by Ocuphire, which is being evaluated in Phase 3 clinical trials for conditions such as presbyopia and low-light vision disturbances following keratorefractive surgery. The company also collaborates with strategic partners to further small-molecule and biologic ophthalmic programs where appropriate.

Opus Genetics serves patients, clinicians, and the broader retinal disease community worldwide. Its value proposition lies in combining world-class gene therapy innovation—rooted in scientific expertise and supported by leading researchers and clinicians—with clinical development experience and capital resources to accelerate regulatory milestones and broaden patient access. The company’s work occurs within a rapidly evolving biotechnology landscape in which genetic medicines are increasingly recognized for their potential to deliver durable, targeted treatments for conditions once considered untreatable.

Headquartered in Research Triangle Park/Durham, North Carolina, Opus Genetics is led by a seasoned management team and board with deep experience in ophthalmology, gene therapy, and translational science. The company positions itself at the intersection of cutting-edge biotechnology and patient-centric innovation, addressing substantial unmet medical needs in rare ophthalmic diseases while pursuing broader applications that could impact millions of patients globally.

Keywords: gene therapy, inherited retinal diseases, IRDs, ophthalmic biopharmaceutical, AAV-based therapies, Leber congenital amaurosis, presbyopia, retinal degeneration, clinical-stage biotech, vision restoration, durable therapies, Durham NC